Answers are grounded in this paper and cite their sources.
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by aberrant cytokine signaling and genetic predisposition. Recent evidence has emerged linking Interleukin-38 (IL-38), an IL-1 family member cytokine, to serving as a putative immunomodulatory mediator of inflammation. This study aimed to examine the role of IL-38 in rheumatoid arthritis and correlate it with inflammatory cytokines, clinical disease activity indices and RA susceptibility genes ( HLA-DRB1 and PTPN22 ) expression. A total of 140 subjects, including 70 rheumatoid arthritis (RA) patients and 70 healthy controls (HC), were included. Clinical parameters were gathered (disease duration, DAS28-ESR, ESR, pain score, tender joint count and swollen joint count). Serum levels of IL-38, IL-6, IL-17 A, TNF-α, RF (rheumatoid factor), anti-CCP antibodies and complement C3 and C4 were measured using immunological assays. Expression levels of HLA-DRB1 and PTPN22 were measured using real-time quantitative PCR, by the 2⁻ΔΔCt method, through the use of GAPDH as an internal reference gene. Cytokine levels were correlated with clinical parameters and gene expression. Rheumatoid arthritis patients had increased serum IL-38 levels compared to healthy controls (154.77 ± 36.72 vs. 82.53 ± 6.75 pg/mL; p < 0.001) and these correlated weakly to moderately with indicators of disease activity, such as DAS28-ESR ( r = 0.40, p < 0.001), ESR ( r = 0.27, p = 0.023) and pain score ( r = 0.30, p = 0.013). IL-38 correlated weakly and positively with main inflammatory cytokines, especially IL-17 A ( r = 0.29, p = 0.014) and TNF-α ( r = 0.30, p = 0.012). Subgroup analysis showed significant differences in IL-38 levels among treatment groups ( p < 0.001) with the highest levels in patients treated with methotrexate and lowest levels observed in patients receiving biologic therapy. In rheumatoid arthritis patients, gene expression analysis showed a significant increase of HLA-DRB1 (4.24 ± 1.79 vs. 1.02 ± 0.21; p < 0.001) and decrease in PTPN22 expression (0.51 ± 0.17 vs. 1.01 ± 0.16; p < 0.001). Moreover, levels of IL-38 correlated weakly and positively with HLA-DRB1 expression ( r = 0.28, p = 0.020), whereas a moderate negative correlation was established for PTPN22 expression ( r = − 0.55, p < 0.001). IL-38 is weakly to moderately correlated with inflammatory cytokines, clinical disease activity and RA susceptibility gene expression, with the exception of a moderate inverse association with PTPN22. These results indicate that IL-38 might be a candidate immunological marker linked to inflammatory signaling systems and genetic susceptibility mechanisms in rheumatoid arthritis, warranting further validation in larger, longitudinal cohorts.
No takes yet. Share an insight, caveat, or question.
Abdul-Samad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: